Опухоли головы и шеи. 2014; : 11-14
ИСПОЛЬЗОВАНИЕ ФАКТОРОВ ПРОГНОЗА В ВЫБОРЕ ТАКТИКИ ЛЕЧЕНИЯ РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/2222-1468-2014-0-1-11-14Аннотация
В статье на значительном клиническом материале приводится анализ результатов лечения больных папиллярным раком щитовидной железы. Изучено влияние различных факторов прогноза на выживаемость пациентов после проведенного хирургического лечения. Предлагается, основываясь на использовании взаимосвязи указанных факторов, определить наиболее оптимальную тактику лечения больных этой формой рака.
Список литературы
1. Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 2007;142(6):906–13 [discussion 913. e1–2].
2. Lin J.D., Chen S.T., Hsueh C., Chao T.C. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007 Jun;17(6):535–41.
3. Mazeh H., Samet Y., Hochstein D. et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011 Jun; 201(6):770–5.
4. Ibrahimpasic T., Nixon I.J., Palmer F.L. et al. Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer – is there a need for radioactive iodine therapy? Surgery 2012;152(6):1096–105.
5. Almeida J.P., Sanabria A.E., Lima E.M., Kowalski L. et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 2011;33(5):686–90.
6. Nixon I.J., Ganly J., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9.
7. Пачес А.И. Опухоли головы и шеи. Кли- ническое руководство. М., 2013. 475 с.
8. Романчишен А.Ф. Клиническое обосно- вание показаний к оперативному лечению заболеваний щитовидной железы. Вестник хирургии 1994;1–2:3–6.
9. Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30.
10. Shah J.P., Loree T.R., Dharker D. et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164(6):658–61.
11. Nixon I.J., Shah J.P. Well differentiated thyroid cancer: are we over treating our patients? Eur J Surg Oncol 2014 Feb;40(2):129–32.
12. Haymart M.R., Benerjee M., Stewart A.K. et al. Use of radioactive iodine for thyroid cancer. JAMA 2011;306(7):721–8.
13. Trovisco V., Soares P., Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006 Jul;37(7):781–6.
14. Wang W., Zhao W., Wang E.U. et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012 Jan;19(1):31–36.
15. Danilovic D.L., Lima E.U., Domingues R.B. et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170(4):619–25.
Head and Neck Tumors (HNT). 2014; : 11-14
USE OF PREDICTORS TO CHOOSE TREATMENT POLICY FOR THYROID CANCER
https://doi.org/10.17650/2222-1468-2014-0-1-11-14Abstract
References
1. Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 2007;142(6):906–13 [discussion 913. e1–2].
2. Lin J.D., Chen S.T., Hsueh C., Chao T.C. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007 Jun;17(6):535–41.
3. Mazeh H., Samet Y., Hochstein D. et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011 Jun; 201(6):770–5.
4. Ibrahimpasic T., Nixon I.J., Palmer F.L. et al. Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer – is there a need for radioactive iodine therapy? Surgery 2012;152(6):1096–105.
5. Almeida J.P., Sanabria A.E., Lima E.M., Kowalski L. et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 2011;33(5):686–90.
6. Nixon I.J., Ganly J., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9.
7. Paches A.I. Opukholi golovy i shei. Kli- nicheskoe rukovodstvo. M., 2013. 475 s.
8. Romanchishen A.F. Klinicheskoe obosno- vanie pokazanii k operativnomu lecheniyu zabolevanii shchitovidnoi zhelezy. Vestnik khirurgii 1994;1–2:3–6.
9. Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30.
10. Shah J.P., Loree T.R., Dharker D. et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164(6):658–61.
11. Nixon I.J., Shah J.P. Well differentiated thyroid cancer: are we over treating our patients? Eur J Surg Oncol 2014 Feb;40(2):129–32.
12. Haymart M.R., Benerjee M., Stewart A.K. et al. Use of radioactive iodine for thyroid cancer. JAMA 2011;306(7):721–8.
13. Trovisco V., Soares P., Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006 Jul;37(7):781–6.
14. Wang W., Zhao W., Wang E.U. et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012 Jan;19(1):31–36.
15. Danilovic D.L., Lima E.U., Domingues R.B. et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170(4):619–25.
